Advanced Tissue-Engineered Therapeutics
Avery Therapeutics, Inc. (“Avery”) is a startup company dedicated to advancing tissue-engineered therapeutics to treat diseases and injuries to human muscle. Avery's lead product, MyCardia™, is a tissue-engineered heart graft developed to treat heart failure and is currently in the pre-clinical development phase. MyCardia™ is positioned to be the world’s first off-the-shelf allogeneic tissue-engineered product for treating heart failure.
More than 23M people worldwide suffer from heart failure—the number one cause of morbidity and mortality in the developed world. In the US, heart failure results in over $39B in treatment costs annually and there are more than 600,000 new cases of heart failure each year. MyCardia™ has the potential to improve heart function and quality of life for patients with heart failure.
A New Way of Treating Heart Failure: MyCardia™
Avery Therapeutics, Inc. is developing innovative cell-based treatments for cardiovascular indications such as heart failure. Our lead product, MyCardia™ is a cryopreserved allogeneic tissue graft that is implanted over damaged heart tissue using minimally invasive techniques.
MyCardia has been tested extensively in pre-clinical models of heart failure demonstrating safety and efficacy. Avery Therapeutics is building on intellectual property that has been exclusively licensed from the University of Arizona.
MyCardia™ is engineered using induced pluripotent stem cells (iPSCs), which were recognized with the Nobel Prize in Physiology or Medicine (2012).
MyCardia™ behaves like cardiac tissue and mimics key molecular attributes of the heart. MyCardia™ is comprised of multiple cell types. Each provides a unique therapeutic role that synergistically repairs the heart.
MyCardia™ is the future of regenerative medicine for the heart. MyCardia™ stimulates the body's repair mechanisms to grow new blood vessels and results in development of new cardiac tissue in treated areas.